arrow
P

Piotr Rutkowski

Maria Sklodowska-Curie National Research Institute of Oncology
H指数:113
被引数:8.7万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Relatlimab plus nivolumab versus nivolumab for advanced melanoma: 5-year survival and biomarker analyses of the phase 3 RELATIVITY-047 trial

瑞利替尼单抗联合纳武利尤单抗对比纳武利尤单抗治疗晚期黑色素瘤:RELATIVITY-047 III期试验5年生存率及生物标志物分析

2026-10-240
OAAI
Long-term efficacy, clinical outcomes, and safety of vimseltinib in patients with tenosynovial giant cell tumor: results from the MOTION phase 3 trial

维美替尼在腱鞘巨细胞瘤患者中的长期疗效、临床结局及安全性:MOTION III期试验结果

2026-10-190
OAAI
Five-year survival with neoadjuvant therapy in melanoma: updated pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)

黑色素瘤新辅助治疗的五年生存率:国际黑色素瘤新辅助治疗协作组(INMC)更新的汇总分析

2026-10-010
OAAI
primary analysis of the RANDOMIZED eortc-2139/columbus-ad trial: Adjuvant encorafenib and binimetinib versus placebo in high-risk stage II BRAF-V600E/K melanoma

随机化EORTC-2139/COLUMBUS-AD试验的初步分析:辅助恩考拉芬尼和比尼替尼与安慰剂在高风险II期BRAF-V600E/K黑色素瘤中的比较

2026-07-210
PRE
IO102-IO103 immune-modulatory cancer vaccine and pembrolizumab in melanoma

IO102-IO103免疫调节性癌症疫苗和帕博利珠单抗在黑色素瘤中的应用

2026-04-210
PRE
Neoadjuvant radiotherapy for primary retroperitoneal well-differentiated liposarcoma: a Transatlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG) propensity score matched analysis

新辅助放疗治疗原发性腹膜后高分化脂肪肉瘤:一项大西洋-澳大拉西亚腹膜后肉瘤工作组(TARPSWG)倾向性评分匹配分析

2026-02-250
OAAI
An updated European Organization for Research and Treatment of Cancer (EORTC) protocol for pathological evaluation of sentinel lymph nodes for Merkel Cell Carcinoma (MCC)

一个更新的欧洲癌症研究与治疗组织(EORTC)关于 Merkel Cell Carcinoma(MCC)哨兵淋巴结病理评估的方案

2026-02-170
PRE
Incidence and risk factors of brain metastases in radically resected melanoma patients: a large international cohort study

根治性切除的黑色素瘤患者脑转移的发生率和危险因素: 一项大型国际队列研究

2026-02-030
OAAI
Body image and perceived limitations in social functioning in the Polish population of basal cell carcinoma patients treated with vismodegib

波兰基底细胞癌患者接受维莫德吉治疗后身体意象与社会功能感知限制

2026-01-010
PRE